KEY TAKEAWAYS: Beken Bio opens new lab at New Orleans BioInnovation Center Facility will support CLIA certification and clinical testing Blood test aims to detect ovarian cancer earlier Expansion strengthens New Orleans’ growing biotech sector   Beken Bio has opened a new laboratory a t the New Orleans BioInnovation Center, marking a key step toward commercializing its ovarian cancer detection test. The biotech startup said the expansion will support the development of a Clinical Laboratory Improvement Amendments (CLIA)-certified facility, a requirement for clinical testing and bringing its diagnostic product to market. The lab is expected to serve as the company’s primary site for clinical and operational activities as it advances regulatory approval. The move strengthens Beken Bio’s footprint in New Orleans and positions the company to accelerate validation of its blood-based test, which is designed to detect ovarian cancer at earlier stages, when treatment outcomes are typically better. “Establishing our lab at NOBIC is a pivotal moment for Beken Bio,” said Christopher Millan, the company’s co-founder and CEO. “This expansion allows us to build the clinical and commercial infrastructure needed to advance our ovarian cancer detection test through regulatory pathways and ultimately bring a life-saving diagnostic to patients.” The laboratory will operate within the New Orleans BioInnovation Center, a nonprofit incubator that provides lab space, resources and industry connections to emerging life sciences companies. Officials at the center said the project reflects its mission to help startups transition from research to commercialization. “Beken Bio’s lab expansion is the kind of milestone NOBIC is built to enable,” said Kris Khalil, the center’s executive director, noting the potential impact of earlier ovarian cancer detection. Ovarian cancer remains the deadliest gynecologic cancer in the United States, and early detection has long been a challenge for clinicians. Beken Bio’s test aims to address that gap by identifying disease earlier through a blood sample. The company’s expansion comes amid broader growth in New Orleans’ bioscience sector, driven by collaboration among startups, academic institutions and economic development groups. By establishing clinical operations locally, Beken Bio is expected to contribute to job creation and further position the region as a hub for biotech innovation. Beken Bio focuses on early cancer detection using nanobiology and machine learning technologies, with the goal of improving outcomes through earlier diagnosis. ...read more read less